Foresight Patient story
Meet the Pantier family
After screening with Foresight, Ashley and her husband discovered that they are both carriers of spinal muscular atrophy, also known as SMA. Knowing the Pantiers’ carrier status allowed physicians to diagnose their children faster and intervene quickly with time-sensitive treatment.
We help you care for everybody
As the pioneer of expanded carrier screening and fetal fraction amplification technology, only Myriad has addressed these factors in inequity in prenatal screening. Our carrier screen and non-invasive prenatal screen are carefully designed to provide reliable and personalized results for every ancestry and BMI.
Learn how Myriad’s prenatal screening can benefit your patients.
Guide patients to make well-informed decisions about:
- Pursuing diagnostic testing
- Consulting with specialists
- Planning for pregnancy and delivery
- Understanding alternative family-building options
Foresight® Carrier Screen
The best detection rate for parents of every ancestry
Carrier screening can identify couples who are at risk of passing inherited disorders to their children. Foresight elevates quality of care by enabling carrier screening for all patients, regardless of family history or ethnicity.
Identifies at-risk couples
Foresight detects 1 in 22 couples at-risk for passing serious and actionable conditions to their children — the highest published detection rate in the industry.2
>99% detection rate for the majority of genes
Be confident in both positive and negative results with >99% detection rates, regardless of ethnicity, for most of the genes in the panel.3
Clear results with pre- and post-screen support
We provide clear, user-friendly results as well as access to board-certified genetic counselors for patient education pre-and post-test.
Prequel® Prenatal Screen with AMPLIFY™ Technology
Early insights into a baby’s development
As early as week 10, Prequel uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for a chromosome abnormality leading to conditions such as Down, Edwards, or Patau Syndromes. These results give your patients more time and information to plan and prepare.
AMPLIFY™ Technology
Prequel is the only NIPS with revolutionary AMPLIFY technology that increases fetal fraction for everybody, including patients with high BMI.1
Answers for patients of all BMIs
With the lowest proven failure rate of 0.1%, Prequel provides reliable and individualized insights for 99.9% of all patients of any BMI.4,5
Individualized results and support
Results that deliver clarity of patients’ true risk with individualized positive-predictive-values (PPV) and residual-risk estimates to help inform next steps.
The Myriad Genetics affordability commitment
Making genetic insights affordable for everybody
We’re committed to making prenatal genetic screening accessible for all patients who can benefit. Our financial assistance program takes into account each patient’s ability to pay, working with them directly to find the best option.
- Broad in-network status with health plans
- 60% of patients qualify for financial assistance and payment plans
- Personalized cost estimates ($150 is the average out-of-pocket cost)
References:
- Welker et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genet Med 23, 443–450 (2021).
- Hogan, et al. Clin Chem 2018; doi:10.1373/clinchem.2018.286823.
- Foresight® Residual Risk Table. https://myriad-library.s3.amazonaws.com/mwh/disease-detection-fact-sheet.pdf.
- Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2020;40(3):333-341. doi:10.1002/pd.5603.
- Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430. doi:10.1002/uog.21904.
